INVOKANA^® (canagliflozin) mode of action

Prescribing Information can be found under Useful Links

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

Postulated TGF mechanisms in normal physiology, early stage diabetic nephropathy and after SGLT2 inhibition

SGLT2 inhibitors lower plasma glucose by inhibiting glucose reabsorption in the proximal tubule of the kidney independently of insulin^13-15

Additionally, they reduce intraglomerular pressure by restoring transforming growth factor (TGF)^13-15

Other mechanisms of renoprotection associated with SGLT2 inhibition may relate to the direct effects of glucose lowering, and improved BP control¹⁵

PP-IN-UK-0238 July 2023

INVOKANA® (canagliflozin) mode of action

Postulated TGF mechanisms in normal physiology, early stage diabetic nephropathy and after SGLT2 inhibition

INVOKANA^® (canagliflozin) mode of action